EleutherobinAlternative Names: BMS 196417
Latest Information Update: 30 Mar 2008
At a glance
- Originator Scripps Institution of Oceanography
- Developer Bristol-Myers Squibb
- Class Antineoplastics; Diterpenes; Eleutherobins
- Mechanism of Action Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer